Sepsis

The FDA approved Bizengri for adults with advanced, unresectable, or metastatic NRG1 fusion-positive cholangiocarcinoma after prior systemic therapy, providing a new targeted option for an ultra-rare and...

The FDA has approved sonrotoclax for adults with relapsed or refractory mantle cell lymphoma who have received prior BTK inhibitor therapy.

The FDA has approved sonrotoclax for adults with relapsed or refractory mantle cell lymphoma who have received prior BTK inhibitor therapy.

The FDA has approved sonrotoclax for adults with relapsed or refractory mantle cell lymphoma who have received prior BTK inhibitor therapy.

The FDA has approved sonrotoclax for adults with relapsed or refractory mantle cell lymphoma who have received prior BTK inhibitor therapy.

The FDA has approved sonrotoclax for adults with relapsed or refractory mantle cell lymphoma who have received prior BTK inhibitor therapy.

The FDA approved a once-daily, 2-drug oral regimen for adults with virologically suppressed HIV-1 to replace existing antiretroviral therapy.

The FDA approved a once-daily, 2-drug oral regimen for adults with virologically suppressed HIV-1 to replace existing antiretroviral therapy.

The FDA approved a once-daily, 2-drug oral regimen for adults with virologically suppressed HIV-1 to replace existing antiretroviral therapy.

The FDA approved a once-daily, 2-drug oral regimen for adults with virologically suppressed HIV-1 to replace existing antiretroviral therapy.